

IN THE CLAIMS**COMPLETE LISTING OF ALL CLAIMS, WITH MARKINGS AND STATUS IDENTIFIERS**

In the revised claim set appearing below, currently amended claims have deletions shown by ~~strike through~~ or brackets [[ ]], and additions shown by underlining. This listing of claims will replace all prior versions and listings of the claims in the application.

Listing of Claims:

1. (canceled)
2. (currently amended) The method ~~A-peptide~~ according to claim [[1]] 6 or 9, wherein said peptide of formula (I) is a peptide wherein
  - A<sup>1</sup> is L-Phe, D-Phe, L-Cpa or D-Cpa;
  - A<sup>3</sup> is L-Tyr, L-Trp or L-3-Pal;
  - A<sup>4</sup> is D-Trp;
  - A<sup>6</sup> is  $\beta$ -Ala or Gaba;
  - A<sup>7</sup> is L-Cys;
  - A<sup>8</sup> is L-Thr, L-Trp, L-Leu or L-Nal; and
  - R<sup>2</sup> and R<sup>3</sup> are each H;
  - or a pharmaceutically acceptable salt thereof.
3. (currently amended) The method ~~A-peptide~~ according to claim [[2]] 6 or 9, wherein said peptide is of the formula
  - Cpa-cyclo(D-Cys-3-Pal-D-Trp-Lys-Gaba-Cys)-Nal-NH<sub>2</sub>;
  - Cpa-cyclo(D-Cys-3-Pal-D-Trp-Lys- $\beta$ -Ala-Cys)-Nal-NH<sub>2</sub>;
  - Phe-cyclo(D-Cys-3-Pal-D-Trp-Lys-Gaba-Cys)-Nal-NH<sub>2</sub>;
  - Phe-cyclo(D-Cys-Tyr-D-Trp-Lys-Gaba-Cys)-Nal-NH<sub>2</sub>;
  - Phe-cyclo(D-Cys-Trp-D-Trp-Lys-Gaba-Cys)-Nal-NH<sub>2</sub>;
  - Phe-cyclo(D-Cys-Tyr-D-Trp-Lys-Gaba-Cys)-Trp-NH<sub>2</sub>;
  - D-Phe-cyclo(D-Cys-Tyr-D-Trp-Lys-Gaba-Cys)-Nal-NH<sub>2</sub>;


D-Phe-cyclo(D-Cys-Tyr-D-Trp-Lys-Gaba-Cys)-Leu-NH<sub>2</sub>; or  
 Phe-cyclo-(D-Cys-Tyr-D-Trp-Lys-Gaba-Cys)-Thr-NH<sub>2</sub>;  
 or a pharmaceutically acceptable salt thereof.

4. (currently amended) The method A-peptide according to claim [[3]] 6 or 9, wherein said peptide is of the formula

Cpa-cyclo(D-Cys-3-Pal-D-Trp-Lys-Gaba-Cys)-Nal-NH<sub>2</sub>; or  
 Cpa-cyclo(D-Cys-3-Pal-D-Trp-Lys-β-Ala-Cys)-Nal-NH<sub>2</sub>;  
 or a pharmaceutically acceptable salt thereof.

5. (currently amended) [[A]] The method according to claim 6 or 9, wherein said peptide or pharmaceutically acceptable salt thereof is in the form of a pharmaceutical composition useful for eliciting a somatostatin agonist response in a human or other animal which comprises an effective amount of a peptide of formula (I) ~~according to claim 1~~ or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.


6. (previously presented) A method of eliciting a somatostatin agonist response in a human or other animal in need thereof, which comprises administering an effective amount of a peptide of formula (I)



(I)

or a pharmaceutically acceptable salt thereof,

wherein



A<sup>1</sup> and A<sup>3</sup> are each independently the D- or L-isomer of an amino acid selected from the group consisting of Phe, Tyr, Tyr(I), Trp, 3-Pal, 4-Pal, Cpa and Nal;

A<sup>4</sup> is L-Trp, D-Trp, L-β-methyl-Trp or D-β-methyl-Trp;

A<sup>6</sup> is -NH-(CHR<sup>1</sup>)<sub>n</sub>-CO-, where n is 2, 3, or 4;

A<sup>7</sup> is L- or D-Cys;

A<sup>8</sup> is the D- or L-isomer of an amino acid selected from the group consisting of Phe, Tyr, Tyr(I), Trp, Nal, Cpa, Val, Leu, Ile, Ser and Thr;

Y is  $\text{NR}^2\text{R}^3$  where  $\text{R}^2$  and  $\text{R}^3$  are each independently H or  $(\text{C}_1\text{-C}_5)\text{alkyl}$ ;

$\text{R}^1$  is selected from the group consisting H,  $(\text{C}_1\text{-C}_4)\text{alkyl}$  and  $-\text{CH}_2\text{-aryl}$ ; wherein said aryl is an optionally substituted moiety selected from the group consisting of phenyl, 1-naphthyl, and 2-naphthyl, wherein said optionally substituted moiety is optionally substituted with one or more substituents each independently selected from the group consisting of  $(\text{C}_{1-6})\text{alkyl}$ ,  $(\text{C}_{2-6})\text{alkenyl}$ ,  $(\text{C}_{2-6})\text{alkynyl}$ , aryl, aryl $(\text{C}_{1-6})\text{alkyl}$ ,  $(\text{C}_{1-6})\text{alkoxy}$ ,  $-\text{N}(\text{R}^4\text{R}^5)$ ,  $-\text{COOH}$ ,  $-\text{CON}(\text{R}^4\text{R}^5)$ , halo,  $-\text{OH}$ ,  $-\text{CN}$ , and  $-\text{NO}_2$ ;

$\text{R}^4$  and  $\text{R}^5$  each is, independently for each occurrence, H or  $(\text{C}_{1-3})\text{alkyl}$ ;


where the Cys of  $\text{A}^2$  is bonded to the Cys of  $\text{A}^7$  by a di-sulfide bond formed from the thiol groups of each Cys,

to the human or other animal.

7. (canceled)

8. (canceled)


9. (currently amended) A method of inhibiting the secretion of growth hormone, insulin, glucagon or pancreatic exocrine secretion in a human or other animal in need thereof, which comprises administering a peptide of formula (I)



(I)

or a pharmaceutically acceptable salt thereof,

wherein



$\text{A}^1$  and  $\text{A}^3$  are each independently the D- or L-isomer of an amino acid selected from the group consisting of Phe, Tyr, Tyr(I), Trp, 3-Pal, 4-Pal, Cpa and Nal;

$\text{A}^4$  is L-Trp, D-Trp, L- $\beta$ -methyl-Trp or D- $\beta$ -methyl-Trp;

$\text{A}^6$  is  $-\text{NH}-(\text{CHR}^1)_n\text{-CO-}$ , where n is 2, 3, or 4;

$\text{A}^7$  is L- or D-Cys;

$A^8$  is the D- or L-isomer of an amino acid selected from the group consisting of Phe, Tyr, Tyr(I), Trp, Nal, Cpa, Val, Leu, Ile, Ser and Thr;

Y is  $NR^2R^3$  where  $R^2$  and  $R^3$  are each independently H or  $(C_1-C_5)$ alkyl;

$R^1$  is selected from the group consisting H,  $(C_1-C_4)$ alkyl and  $-CH_2$ -aryl; wherein said aryl is an optionally substituted moiety selected from the group consisting of phenyl, 1-naphthyl, and 2-naphthyl, wherein said optionally substituted moiety is optionally substituted with one or more substituents each independently selected from the group consisting of  $(C_{1-6})$ alkyl,  $(C_{2-6})$ alkenyl,  $(C_{2-6})$ alkynyl, aryl, aryl $(C_{1-6})$ alkyl,  $(C_{1-6})$ alkoxy,  $-N(R^4R^5)$ ,  $-COOH$ ,  $-CON(R^4R^5)$ , halo,  $-OH$ ,  $-CN$ , and  $-NO_2$ ;

$R^4$  and  $R^5$  each is, independently for each occurrence, H or  $(C_{1-3})$ alkyl;

where the Cys of  $A^2$  is bonded to the Cys of  $A^7$  by a di-sulfide bond formed from the thiol groups of each Cys,

to said human or other animal.

10. (canceled)

11. (canceled)